Visual symptoms are a vital component of the morbidity encountered in patients with pituitary adenoma, can present at all stages of the disease, and may negatively affect daily activities and overall quality of life, a new review claims.
Unlike previous studies, the researchers found that in their practice, no-treatment rates between elderly and nonelderly patients with biopsy-proven NMSCs were significantly different.
AbbVie has halted enrollment in all ongoing studies of depatuxizumab mafodotin, after an Independent Data Monitoring Committee (IDMC) recommended a phase 3 study of the treatment be stopped due to a lack of survival benefit.
This study involved the engineering of CAR-T cells specific for the EGFRvIII antigen to also secrete bispecific T cell engagers (BiTEs) against wild-type EGFR.
Neoadjuvant administration of programmed cell death protein 1 (PD-1) blockade seems to enhance local and systemic antitumor immune response in glioblastoma.
